| 1/3/2019 | BKCV | Moody's puts Celgene on upgrade review
|
| 10/26/2017 | CV | Market Commentary: Weibo jumps; China Lodging on tap; Depomed eyed as Trump takes aim at ‘opioid crisis’
|
| 11/19/2007 | CV | Market Commentary: Celgene hit on merger; United Rentals hurt on breakup; Ford, GM fall on fears mortgage mess spreading
|
| 2/26/2007 | CVSP | New Issue: Citigroup prices $55.75 million 12% ELKS linked to Celgene
|
| 11/3/2006 | BTCV | Celgene files automatic shelf registration
|
| 6/28/2006 | BTCV | New Issue: Barclays sells $2 million 13.5% exchangeables linked to Celgene
|
| 6/8/2006 | CV | Barclays plans issue of 13.5% exchangeables linked to Celgene
|
| 2/7/2006 | BTCV | New Issue: Goldman Sachs prices $52.12 million 0% trigger notes mandatorily exchangeable for Celgene
|
| 11/30/2005 | BTCV | New Issue: Barclays sells $1.5 million 12% exchangeables linked to Celgene
|
| 11/4/2005 | CV | Market Commentary: Qwest, Chesapeake remain active; Celgene up, Emdeon lower; King sideways
|
| 10/3/2005 | CV | Market Commentary: Celgene rebounds; Medtronic firm; School Specialty drops; NRG eyes $500 million mandatory preferred
|
| 7/20/2005 | CV | Market Commentary: Amgen rises in mixed convertibles trading as earnings reports roil GM, Kodak, boost Wyeth
|
| 7/8/2005 | CV | Market Commentary: Biotechs, chips lead convertibles mostly higher; Charming Shoppes, Henry Schein trade higher
|
| 3/7/2005 | CV | Market Commentary: Genworth synthetic coming; Cell Therapeutics dives; Celgene rises; Saks bagged up; Lions Gate higher
|
| 4/28/2004 | CV | S&P: Celgene unaffected
|
| 4/26/2004 | CV | Market Commentary: OSI Pharma skyrockets amid buying frenzy as stock shoots up 139%; 4 new deals emerge
|
| 6/9/2003 | CV | Market Commentary: Week begins slowly with a thin market; Omnicare prices, three more small deals emerge
|
| 5/30/2003 | CV | Celgene greenshoe exercised, raising convertibles to $400 million
|
| 5/29/2003 | CV | New Issue: Celgene $325 million convertibles yield 1.75%, up 50%
|
| 5/29/2003 | CV | Market Commentary: Lucent upsized to $1.525 billion, premium price talk revised on strong demand
|
| 5/28/2003 | CV | Market Commentary: Market attention drawn to new issues as Delta and Juniper get reoffered at lower prices
|
| 5/28/2003 | CV | Celgene $300 million convertible talked to yield 1.75 to 2.25%, up 45-50%
|
| 12/21/2001 | CV | Celgene files $500 million debt, stock, convertible shelf
|
